ESHG
Berlin, Germany
1-4 June
Berlin, Germany
1-4 June
Join us for the
Asuragen, a Bio-Techne brand’s unique and proprietary AmplideX® and QuantideX® chemistries power simple and streamlined solutions for analysis of complex genomic targets.
Visit us at stand #516
We are committed to advancing equitable healthcare by offering comprehensive genetic coverage. Our extensive range of genetic tests and services ensures patients receive accurate diagnoses, personalized treatment plans, and improved outcomes.
We are proud to share our innovative approaches to cancer monitoring and management. Through state-of-the-art technologies and groundbreaking research, we strive to revolutionize cancer care by early detection, targeted therapies, and effective management strategies.
Meeting Room New York 1
Sunday 2 June, 12:00-13:00 CEST
Dr. John Milligan
R&D Director, Asuragen, a Bio-Techne brand
Prof. Anne-Sophie Lebre
Professor at the University of Reims
Champagne-Ardenne, Consultant Reims University Hospital
Beta Evaluation of the AmplideX® PCR Enrichment Technology with ONT Long-Read DNA Sequencing of a Panel of Eleven Challenging Genes
Combining AmplideX PCR Chemistries, Nanopore Sequencing, and Automated Analysis Software to Genotype Complex, Genetic Variants in 11 Challenging Targets Associated with Hereditary Diseases
AmplideX® Nanopore Carrier Plus Kit*†
A Long-Range PCR and Long-Read Sequencing Solution for Carrier Screening
*For research purpose only. Not for use in diagnostic procedures.
†This product is under development; performance characteristics and final product features to be determined.